ZÜRICH, Switzerland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics based on its proprietary antibody-based MHC-targeting T cell engager technology, today announced the appointment of Swethajit Biswas, MD, FRCP to the position of Chief Medical Officer, effective immediately.
ZURICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics...
ZÜRICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by CDR-Life, please note that in the second paragraph of the release, the...
ZÜRICH, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., today announced that Boehringer Ingelheim has selected an antibody fragment-based therapeutic candidate for advancement to the next phase of development under the existing agreement between the companies for the discovery and development of novel therapies for the treatment of geographic atrophy (GA), triggering an undisclosed milestone payment from Boehringer Ingelheim to CDR-Life. GA is a blinding retinal disease that occurs in patients with age-related macular degeneration (AMD) and for which there is no treatment.